Solanezumab fails to significantly slow cognitive decline – new data published

Written by Lauren Pulling, Senior Editor

In the much-anticipated follow-up from Eli Lilly and Company’s (IN, USA) EXPEDITION3 trail, data have published reporting that solanezumab did not significantly slow cognitive decline in patients with mild dementia due to Alzheimer’s disease (AD). The paper, published in the New England Journal of Medicine, reports that 2129 patients with mild dementia due to AD participated in the double-blind, placebo-controlled, Phase III multicenter trial. While some favorable outcomes were reported, the primary outcome measure, assessed with the AD Assessment Scale-cognitive subscale, was not met, with no statistically significant benefit observed compared with the placebo. The paper concludes that solanezumab at...

To view the full article, please register now for access

It's completely free